A new three-drug combination for high-risk blood cancers with a TP53 change
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a three-drug combination (selinisole, azacitidine, and venetoclax) for newly diagnosed high-risk blood cancers with a TP53 gene change. These drugs aim to target the cancer while skipping standard chemotherapy, possibly making treatment more effective and less harsh.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with a type of blood cancer (like MDS, AML, or MPN) that has a TP53 gene change and is considered high-risk or aggressive.
- You have not yet started your first treatment for this blood cancer.
- Your liver and kidney function are within acceptable limits, and you are generally well enough to be up and about (ECOG score 2 or lower).
- You do not have active hepatitis B or C, HIV, or uncontrolled heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, selinexor and azacitidine, for people with high-risk blood cancers like acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The goal is to see if this combination can help control the disease, especially before a stem cell transplant.
This study tests whether adding a drug called selinexor to a standard chemo-immunotherapy combination (called R-GDP) can help people whose large B-cell lymphoma has a TP53 gene change and has not responded to earlier treatment. The goal is to see if this combination helps control the lymphoma.
This trial studies whether selinexor combined with azacitidine and venetoclax can treat newly diagnosed acute myeloid leukemia (AML) in people who may not be able to tolerate intensive chemotherapy. It’s aimed at improving leukemia control with a treatment approach designed for patients with higher risk from other health problems.
This trial tests adding selinexor to the standard R-CHOP chemotherapy for people with a specific type of diffuse large B-cell lymphoma (DLBCL) that has a TP53 mutation. The goal is to see if this combination works better as the first treatment.
This trial tests a new drug (axatilimab) combined with two standard chemotherapy drugs (decitabine and venetoclax) for people with acute myeloid leukemia (AML) that has a TP53 mutation. The goal is to see if this combination helps control the cancer better than current treatments.
This Phase 1 trial tests whether selumetinib and azacitidine can help people with high-risk chronic blood cancers. You may qualify if your disease is higher risk and has either come back, not responded, or needs treatment because of low blood counts or other concerning features.
Hear when a new Myeloid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.